Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716663 · ClinicalTrials.gov registry record
CARTO® 3 System and Real Time Intracardiac Ultrasound
A clinical trial, sponsored by Biosense Webster.
- Completed
- Registry status
- 234
- Enrollment target
NCT01716663: Completed study, sponsored by Biosense Webster.
NCT01716663 is a clinical trial that has completed, run by Biosense Webster. The registered enrollment target is 234 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01716663 has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- 234 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, non-randomized observational study of subjects 18 years and older undergoing RF ablation with drug refractory recurrent symptomatic paroxysmal Atrial Fibrillation (AF).
Primary Outcome
The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure and summed to derive the total.
Interventions
- DEVICE Catheter Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-09 |
What the finished NCT01716663 record still lists
NCT01716663 is an observational study that tracks outcomes without assigning an intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Catheter Ablation is the first listed.
NCT01716663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01716663 about?
NCT01716663 is a clinical study titled "CARTO® 3 System and Real Time Intracardiac Ultrasound". This is a prospective, multicenter, non-randomized observational study of subjects 18 years and older undergoing RF ablation with drug refractory recurrent symptomatic paroxysmal Atrial Fibrillation (AF).
What is the current status of trial NCT01716663?
This trial is currently completed. The enrollment target is 234 participants. The study started on 2012-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01716663?
The interventions under investigation include: Catheter Ablation (DEVICE).
Who is sponsoring clinical trial NCT01716663?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia